These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24521874)

  • 1. Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Burn DJ; Kass-Iliyya L; Kellett MW; Crossman AR; Silverdale MA
    Parkinsonism Relat Disord; 2014 Apr; 20(4):452-5. PubMed ID: 24521874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease.
    Wong KK; Alty JE; Goy AG; Raghav S; Reutens DC; Kempster PA
    Mov Disord; 2011 Jul; 26(8):1552-5. PubMed ID: 21538524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients.
    Tison F; Nègre-Pagès L; Meissner WG; Dupouy S; Li Q; Thiolat ML; Thiollier T; Galitzky M; Ory-Magne F; Milhet A; Marquine L; Spampinato U; Rascol O; Bezard E
    Parkinsonism Relat Disord; 2013 Apr; 19(4):416-21. PubMed ID: 23283428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease.
    Silverdale MA; Nicholson SL; Crossman AR; Brotchie JM
    Mov Disord; 2005 Apr; 20(4):403-409. PubMed ID: 15593312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
    Berg D; Godau J; Trenkwalder C; Eggert K; Csoti I; Storch A; Huber H; Morelli-Canelo M; Stamelou M; Ries V; Wolz M; Schneider C; Di Paolo T; Gasparini F; Hariry S; Vandemeulebroecke M; Abi-Saab W; Cooke K; Johns D; Gomez-Mancilla B
    Mov Disord; 2011 Jun; 26(7):1243-50. PubMed ID: 21484867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Fox SH; Metman LV; Nutt JG; Brodsky M; Factor SA; Lang AE; Pope LE; Knowles N; Siffert J
    Mov Disord; 2017 Jun; 32(6):893-903. PubMed ID: 28370447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
    Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE
    N Engl J Med; 2000 May; 342(20):1484-91. PubMed ID: 10816186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
    Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S
    Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
    Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
    Stathis P; Konitsiotis S; Tagaris G; Peterson D;
    Mov Disord; 2011 Feb; 26(2):264-70. PubMed ID: 21412833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
    Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
    Kobylecki C; Hill MP; Crossman AR; Ravenscroft P
    Mov Disord; 2011 Nov; 26(13):2354-63. PubMed ID: 21953539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA
    Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
    Nutt JG; Carter JH; Carlson NE
    Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
    Fox S; Silverdale M; Kellett M; Davies R; Steiger M; Fletcher N; Crossman A; Brotchie J
    Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
    Trenkwalder C; Berg D; Rascol O; Eggert K; Ceballos-Baumann A; Corvol JC; Storch A; Zhang L; Azulay JP; Broussolle E; Defebvre L; Geny C; Gostkowski M; Stocchi F; Tranchant C; Derkinderen P; Durif F; Espay AJ; Feigin A; Houeto JL; Schwarz J; Di Paolo T; Feuerbach D; Hockey HU; Jaeger J; Jakab A; Johns D; Linazasoro G; Maruff P; Rozenberg I; Sovago J; Weiss M; Gomez-Mancilla B
    Mov Disord; 2016 Jul; 31(7):1049-54. PubMed ID: 26990766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
    Tousi B; Subramanian T
    Parkinsonism Relat Disord; 2005 Aug; 11(5):333-4. PubMed ID: 15949966
    [No Abstract]   [Full Text] [Related]  

  • 20. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group.
    Ann Neurol; 1997 Nov; 42(5):747-55. PubMed ID: 9392574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.